CORT Share Price Performance
US$79.78
20.57 (34.74%)
40.7% undervalued intrinsic discount
US$134.50
Fair Value
Price US$79.78
AnalystConsensusTarget US$134.50
Fair ValueUS$134.50
Share Pricen/a
Corcept Therapeutics Incorporated Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 115 Fair Values set on narratives written by author
CORT Community Narratives
AN
Fair Value US$134.5 40.7% undervalued intrinsic discount
Patient Screening And Regulatory Approvals Will Unlock Global Markets
0users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
Patient Screening And Regulatory Approvals Will Unlock Global Markets
Key Takeaways Expanding disease awareness, anticipated drug approvals, and enhanced commercial operations are set to propel revenue growth and decrease reliance on a single product. Favorable demographic trends and proven regulatory execution support ongoing market and earnings expansion for the company.Read more
0users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
AN
US$134.5
40.7% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
40.67% p.a.
Profit Margin
37.28%
Future PE
23.58x
Price in 2028
US$163.46
Trending Discussion
Recently Updated Narratives
AN
Patient Screening And Regulatory Approvals Will Unlock Global Markets
Fair Value: US$134.5 40.7% undervalued intrinsic discount
57 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Corcept Therapeutics Incorporated Key Details
About CORT
- Founded
- 1998
- Employees
- 500
- CEO
- WebsiteView website
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
